Adial Pharmaceuticals Partners With Crown CRO to Begin Phase 3 Clinical Trials of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, and Crown CRO, a contract research organization based in Finland, today announced Crown’s engagement to manage Adial’s Phase 3 clinical trial for AD04 for the treatment of alcohol use disorder (AUD). The FDA approved protocol for this Phase 3 clinical trial is a 24-week trial with 290 patients in 30 clinical sites in 5 European countries.

Read more from Adial Pharmaceuticals’ press release